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Abstract
Introduction: Pharmacological agents that block beta-adrenergic receptors have been associated with improved
outcome in burn injury. It has been hypothesized that injuries leading to a hypermetabolic state, such as septic shock,
may also benefit from beta-blockade; however, outcome data in experimental models have been contradictory. Thus,
we investigated the effect of beta-blockade with propranolol on survival, hemodynamics, lung heat shock protein
(HSP) expression, metabolism and inflammatory markers in a rat cecal ligation and puncture (CLP) model of sepsis.
Methods: Sprague-Dawley rats receiving either repeated doses (30 minutes pre-CLP and every 8 hours for 24
hours postoperatively) of propranolol or control (normal saline), underwent CLP and were monitored for survival.
Additionally, lung and blood samples were collected at 6 and 24 hours for analysis. Animals also underwent
monitoring to evaluate global hemodynamics.
Results: Seven days following CLP, propranolol improved survival versus control (P < 0.01). Heart rates in the
propranolol-treated rats were approximately 23% lower than control rats (P < 0.05) over the first 24 hours, but the
mean arterial blood pressure was not different between groups. Metabolic analysis of lung tissue demonstrated an
increase in lung ATP/ADP ratio and NAD+ content and a decreased ratio of polyunsaturated fatty acids to
monounsaturated fatty acids (PUFA/MUFA). Cytokine analysis of the inflammatory cytokine tumor necrosis factor
alpha (TNF-alpha) demonstrated decreased expression of TNF-alpha in both lung and plasma at 24 hours post CLP
induced sepsis. Finally, propranolol led to a significant increase in lung hemeoxygenase-1 expression, a key cellular
protective heat shock protein (HSP) in the lung. Other lung HSP expression was unchanged.
Conclusions: These results suggest that propranolol treatment may decrease mortality during sepsis potentially via
a combination of improving metabolism, suppressing aspects of the inflammatory response and enhancing tissue
protection.
Introduction
Pharmacological agents that block beta-adrenergic recep-
tors are frequently used in critically ill patients. Over 30
years ago Berk et al. demonstrated that beta-blockers
may reduce mortality from both experimental and
clinical sepsis and shock [1]. This hypothesis has been
revisited recently with new data demonstrating cardiac
and metabolism related-benefits to beta-blocker therapy
in experimental and clinical critical care settings. Specifi-
cally, beta blockade has been used to prevent catechola-
mine-mediated hypermetabolism and improve cardiac
performance in critically ill patients suffering from severe
trauma or burn injury [2-6]. These beneficial effects were
not associated with any increase in the incidence of
hypotension, infection or inflammation [5,7].
Recent reviews propose that beta-blockers may have pro-
tective effects in septic patients [8-10]. Although clinical
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data are mainly limited to case reports, a recent study
demonstrated that patients receiving beta-blockers who
subsequently develop sepsis experienced a survival advan-
tage compared to patients not previously receiving beta
blocker therapy [11]. However, laboratory data indicate
conflicting results on the role of beta-blockers in improving
survival from sepsis. While it has been hypothesized that
the potential beneficial effects of beta-blocker therapy in
sepsis are in part due to immune regulation, the effect of
beta-blocker therapy on cytokine expression is unclear.
Conflicting results have shown that beta-blockade can lead
to either an increase or decrease in cytokine expression
and immune regulation depending on the experimental
model, class of beta blockade (specific versus non-specific)
and where the cytokine was measured (organ, plasma and
so on) [8]. Confounding all of the pre-clinical data is the
fact that these studies utilize a wide range of sepsis models,
doses, co-interventions (such as catecholamines),
beta-blocker classes and timing of therapy.
Although the demonstrated survival benefit of beta-
blockade during sepsis may be due to direct myocardial
protective effects, hemodynamic/catecholamine-mediated
changes, or immune regulation, there remain other poten-
tial benefits of beta-blockade that have not been explored.
One of those effects may involve activation of stress-indu-
cible protein systems, or heat shock proteins (HSPs) that
cells use to maintain cellular homeostasis during stress
and inflammation. Data found by Herndon et al via gene-
array for RNA expression indicate that propranolol can
upregulate gene-expression for key stress-response
proteins in muscle biopsies from burned children [12].
These data showed that a member of the HSP 70 family
(GRP70) was significantly upregulated in the muscle of
patients treated with propranolol. No further exploration
of this potential organ protective pathway examining other
stress proteins or other tissues has been described.
Much of the recent experimental data on beta-blockers
in sepsis have focused on the myocardial and whole body
metabolic effects of propranolol in sepsis and injury [13].
Given the conflicting data on the effects of beta blockade
during sepsis on metabolism, survival, cardiac performance
and immune regulation, further studies, particularly studies
examining other organs such as the lung, are needed.
The aim of this study was to investigate the effect of
non-specific beta blockade with propranolol on cecal liga-
tion and puncture (CLP)-induced sepsis in the rat and to
examine the effect of this therapy on survival, overall
hemodynamics and, specifically, on lung tissue cytokine
expression, lung metabolism and lung HSP expression.
Materials and methods
Animals and experimental protocol
The animal experiments described in this paper were
performed in adherence to the National Institute of
Health guidelines for the use of experimental animals.
The Animal Care and Use Committee of the University
of Colorado, Denver, approved all animal protocols. All
experiments were also conducted and the animals cared
for in accordance with the Guiding Principles for
Research Involving Animals and Human Beings of the
American Physiological Society.
Animals used in these experiments were male Sprague-
Dawley rats with a body weight between 300 and 350 g
purchased from Harlan (Madison, WI, USA). They were
maintained on a standard diet (Teklad rat chow; Harlan)
and water ad libitum. They were allowed an acclimatization
period of at least 14 days before the procedure. They were
housed at a constant temperature (69 to 71°F) with light
and dark cycles of 10 hours and 14 hours, respectively.
The CLP method was utilized as previously described
[14]. Thirty minutes prior to CLP, the animals were divided
into two groups and given propranolol (10 mg/kg) through
an intraperitoneal injection or normal saline of the same
volume and same administration route. Then, following
anesthesia with an intraperitoneal injection of ketamine (80
mg/kg) and xylazine (12 mg/kg), a 2 cm incision was made
near the lower midline of the abdomen and the cecum was
exposed. 30% of the cecum was then ligated using 3.0 silk
just below the ileocecal valve (to avoid bowel obstruction).
This percentage of cecum ligation was chosen for its repro-
ducible rate of mortality in control animals [15]. The
ligated portion of the cecum was then punctured twice
with an 18 g needle and a small amount of the contents
were expelled into the peritoneal cavity. Following this, the
cecum was returned to its original location within the
abdomen, and both the muscle and skin layers were closed.
No antibiotics were administered; however, 20 cc/kg nor-
mal saline was given subcutaneously as fluid resuscitation.
The animals were then returned to their cages and allowed
access to chow and water ad libitum.
Propranolol administration
Thirty minutes prior to CLP, the animals were randomly
divided into two groups and given either propranolol (10
mg/kg) through an intraperitoneal injection or normal
saline (non-propranolol treated septic control) of the same
volume and same administration route. The doses men-
tioned above of either propranolol or saline were given
every eight hours postoperatively for 24 hours.
Survival studies
33 animals (16 propranolol-treated and 17 non-propra-
nolol treated septic control animals) were observed at
regular intervals for occurrence of mortality over the
subsequent seven days and survival time was recorded.
Moribund animals (defined as bradycardia to a heart
rate less then 40; severe lethargy; and unresponsive to
painful stimulation) were sacrificed with a lethal dose of
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ketamine/xylazine as defined by the University of Color-
ado Animal Care Committee.
Hemodynamic monitoring
A second group (n = 4/group) of animals underwent the
same procedures and heart rate and blood pressure
were recorded at regular intervals to evaluate the hemo-
dynamic effects of propranolol in our CLP model. An
invasive hemodynamic monitoring system (HP 78352C
monitor, Hewlett Packard, Avondale, PA, USA) via a
carotid arterial catheter was utilized.
Quantification of lung tissue metabolites
A third set of animals (n = 5/group) followed the afore-
mentioned treatments and lung tissue was harvested at
6 hours and 24 hours for analysis of lung tissue metabo-
lism. Snap frozen lung tissue was extracted with per-
chloric acid as described in detail by Serkova et al. [16].
After centrifugation, the supernatants were analyzed by
multinuclear NMR metabolomics or magnetic resonance
spectroscopy (MRS) as described previously [16]. Tis-
sue-specific metabolites quantified by multinuclear
NMR metabolomics included lung tissue ATP/ADP
ratio, high energy phosphates (ATP, ADP, nicotinamide
adenine dinucleotide (NAD+)) and lactate, glutathione
and lipids/phospholipids.
TNF-a analysis
Additional animals (n = 4 per group/time point) were
treated via the same procedure as mentioned above;
however, they were sacrificed for blood and lung tissue
at 6 and 24 hours post CLP. All tissues were washed in
1X PBS after removal and then frozen at -80°C. The
plasma and lung tissue was analyzed by ELISA for TNF-
a using a Rat TNF-a ELISA kit. (Thermo Scientific
Pierce, Rockford, IL, USA)
Heat shock protein analysis
Lung tissue was also collected at 6 and 24 hours post
CLP (n = 4 per group/time point) for HSP expression.
All tissues were washed in 1X PBS after removal and
then frozen at -80°C. For whole cell protein expression
levels, tissues were homogenized with Mammalian Pro-
tein Extraction Reagent (M-PER) (Thermo Scientific,
Waltham, MA, USA) plus protease inhibitors. Protein
was determined and western blots were run to evaluate
beta-actin, HSP25, HSP70 and HO-1 protein expression
as previously described [17].
Statistical analysis
As this was a pilot study of the effect of propranolol on
lung protection and inflammatory/metabolic response in
sepsis, limited preliminary data were available by which
to predict an effect on survival in our model. Thus, to
attempt to identify a meaningful survival effect we set a
difference of 40% in mortality as our baseline desired
effect. We performed the sample size calculation using
the following formula: n = (2/d2) × Cp, power, where n
is the number of mice needed in each group, d is the
standard difference (d = target difference/standard
deviation) and Cp, power, is a constant defined by a P-
value of 0.05 and power of 80%. The number of mice
required to detect a 40% difference in mortality assum-
ing a standard deviation of 0.4 to 0.5 was 16 to 25.
When 16 and 17 animals per group, respectively, were
reached analysis of the observed mortality difference
was performed and a statistical difference was observed.
To minimize animal exposure to this potentially lethal
model we chose not to conduct further survival data
when a statistically significant mortality difference was
achieved. All statistics were run using Microsoft Office
Excel (2007) and SAS 9.2. Student’s t-tests were per-
formed to determine differences between the means of
TNF-a, ATP/ADP ratio, NAD+ content and PUFA/
MUFA ratio. Mann Whitney tests were performed to
determine differences between heart rate and mean
arterial pressure (MAP) variables at specific time points.
Averages are reported as mean +/- SD. A Kaplan-Meier
analysis and log-rank test were used to analyze survival
data. Differences were considered significant if the P-
value was less than or equal to 0.05.
Results
Propranolol treatment improves overall survival without
significant change in blood pressures in a rat model of
sepsis
Survival was increased in Sprague-Dawley rats that
received propranolol compared with the non-proprano-
lol treated septic control group following CLP-induced
sepsis (log-rank test; P < 0.05) (Figure 1). Overall
Figure 1 Kaplan-Meier curve of survival times in control and
propranolol groups. There was significantly increased survival in
rats that received propranolol compared with the control group
following CLP induced sepsis (log-rank; P < 0.05). CLP, cecal ligation
and puncture.
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mortality at seven days was significantly lower in rats
that received propranolol compared to rats that received
saline (69% survival rate in propranolol rats (11 out of
16) versus 23% survival in control rats (4 out of 17), P <
0.01). Heart rates (Figure 2A) for propranolol-treated
rats ranged between 23% to 34% lower than control rats
and were significantly lower than control rats at 6, 12
and 24 hours post sepsis onset (P < 0.05). However, the
MAP remained stable with no statistical difference
between the two groups (Figure 2B).
Propranolol improves metabolic function in lung tissue
following sepsis
In order to assess the effect of propranolol on tissue
metabolism, NMR metabolism studies were performed
in lung tissue at 6 and 24 hours post onset of sepsis
(Table 1). No significant changes were observed in
lactate content, total glutathione or other fatty acid con-
tent (not shown). A decrease in ATP/ADP ratio was
observed in both groups versus our previously published
non-septic, healthy control animal data (normal
untreated control ATP/ADP ratio 3.51 +/- 0.58) [18].
There was a significant increase in lung ATP/ADP ratio
in propranolol treated rats at six hours post onset of
sepsis compared to untreated septic control rats (P <
0.05, 95% CI -0.67 to -0.05) but no significant difference
was observed at 24 hours. There was significantly
increased lung NAD+ content in propranolol treated
rats at 24 hours post onset of sepsis compared to the
untreated septic control rats (P < 0.01, 95% CI -0.59 to
-0.07). Also, there was a significant increase in the lung
[PUFA/MUFA] ratio in propranolol-treated rats at 24
hours post onset of sepsis (P < 0.05, 95% CI -2.2 to
-0.06).
Propranolol reduces TNF-a expression in lung and plasma
TNF-a was analyzed to assess the effect of propranolol on
pulmonary and systemic inflammation. ELISA of lung
homogenates revealed similar levels of TNF-a between
groups at six hours but decreased levels of TNF-a at 24
hours post sepsis onset in propranolol treated rats com-
pared to control rats (Figure 3A, P <0.05, 95% CI -293.4 to
-1.7). Also, there was a significant decrease in lung TNF-a
concentration in propranolol treated rats at 24 hours
when compared to six hours post sepsis onset (P <0.05,
95% CI -19.1 to -0.2). The untreated septic control rats
did not demonstrate a significant decrease from 6 to 24
hours. Plasma TNF-a levels were also decreased in
propranolol treated rats when compared with untreated
septic control rats (Figure 3B, P <0.05) at 24 hours post
sepsis onset.
Propranolol increases HO-1 expression, but not other
heat shock protein expression in the lung following
sepsis
Levels of HSPs were analyzed in the lung at 6 and
24 hours post sepsis onset. This analysis included HSP70,
HSP 25, GRP 78 and HO-1. These specific proteins were
chosen because they have been shown to be key in lung
protection in our previous experimental sepsis data (HSP
70, HSP 27, HO-1) [18,19] and propranolol has been
shown to induce these proteins in the muscle of burned
pediatric patients (HSP 70, GRP 78) [12]. As shown in
Figure 4, propranolol treatment did not affect lung HSP
expression, with the exception of HO-1 (hemeoxygenase-1
or HSP 32). Similar levels of HO-1 and all other measured
HSPs were observed between the groups at six hours.
However, at 24 hours following sepsis onset, propranolol
treated rats had significantly increased levels of lung HO-1
compared to untreated septic control rats (Figure 4, P <
0.05, 95% CI -0.8 to -0.02).
Figure 2 Heart rate and MAP in control and propranolol
groups. A) There was a significant decrease in mean heart rate
observed in the propranolol group (n = 4/group, *-P < 0.05,
**-P < 0.01) at 8, 12 and 24 hours. B) There was no significant
difference in MAP between the groups at any time point (n = 4/
group). MAP, mean arterial pressure.
Table 1 Effect of propranolol on metabolic function in
the lung following sepsis


















5.83 +/- 2.75 2.42 +/-
0.82
3.53 +/- 0.56b
All values are reported as mean +/- S.D. and expressed as micromoles/gram of
tissue except for ratio (ATP/ADP). aP < 0.05 when compared to saline at 6 hr.
bP < 0.05 when compared to saline at 24 hour. (n = 5/group/timepoint). NAD
+, nicotinamide adenine dinucleotide; PUFA/MUFA, polyunsaturated fatty acids
to monounsaturated fatty acids.
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Discussion
This study demonstrates that non-specific beta-blockade
with propranolol improves survival in septic rats without
evidence of hemodynamic compromise. Furthermore, for
the first time we show that propranolol may improve
metabolic function in the lungs with significant increases
in the ATP/ADP ratio and NAD+ content and a signifi-
cant decrease in the PUFA/MUFA ratio. Additionally,
propranolol affected cytokine expression by decreasing
TNF-a levels in both plasma and lung samples. Also, this
study is the first to show that propranolol can increase
the key tissue protective protein HO-1 in the lung follow-
ing sepsis.
Our data are the first to show that non-specific beta
blockade with propranolol can prolong survival in an
experimental sepsis model. While few published studies of
beta-blockade in experimental sepsis report mortality data,
the reports are conflicting. This is likely due to variability
in animal sepsis models, specificity of beta-receptor block-
ade, dosage and timing of treatment [20]. In a CLP rat
model of sepsis similar to our study, beta-1 specific block-
ade demonstrated a clear survival advantage [21]. Conver-
sely, in a CLP murine model of sepsis where non-specific
beta blockade was used, mortality was increased in propra-
nolol treated mice [22]. Unlike our study, however, these
studies in mice did not utilize any type of hemodynamic
monitoring and were unable to assess if there were pro-
pranolol-induced changes in local or systemic perfusion.
A.
B. 
Figure 3 Effect of propranolol on TNF-a expression. A) Lung
TNF-a in control and propranolol groups. There were similar levels
of TNF-a between groups at 6 hours. At 24 hours post sepsis onset
propranolol treated rats had significantly lower TNF-a compared to
saline rats at 24 hours. B) Plasma TNF-a in control and propranolol
groups. At 24 hours post sepsis onset propranolol treated rats had
significantly lower TNF-a compared to saline treated rats at 24
hours. Error bars represent standard deviation and significance
markers shown by brackets on figure (n = 4/group).
Figure 4 Heat shock protein (HSP) expression in propranolol
and control groups. Mean relative densitometry of all HSPs
normalized to beta-actin. No changes in HSP expression were
noted, with the exception of HO-1 expression. There were similar
levels of HO-1 between groups at 6 hours. At 24 hours post sepsis
onset propranolol treated rats had significantly higher levels of HO-
1 compared to saline treated rats (*-P < 0.05). Error bars represent
standard deviation. Image representative of HSP expression and
beta-actin from the lungs in saline and propranolol groups at 6 and
24 hours. Error bars represent standard deviation (n = 4/group).
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Additionally, in these studies beta-blockade was initiated
at various time points often at the time of surgery or
following the procedure. In our study, which demon-
strated improved survival, propranolol treatment was
initiated prior to the CLP procedure which is consistent
with a recent study by Ackland et al. demonstrating that
beta-blockade before but not after induction of sepsis
provided a significant survival advantage [21]. Clinical
studies on the survival benefit of beta-blockade in sepsis
are limited to only a few case reports and a recent study
demonstrating that patients previously on chronic
beta-blocker therapy had decreased mortality when
admitted to the ICU for sepsis compared to patients not
on chronic beta-blockers. Future clinical studies will hope-
fully shed light on this issue. Currently, there is at least
one clinical trial ongoing to investigate outcomes of
beta-blockade in sepsis [23].
One of the major limitations of non-specific beta-block-
ade is a potential effect on local and systemic perfusion
and in the clinical setting ICU physicians are constantly
monitoring hemodynamics and adjusting treatment
accordingly [13]. For this reason, this study was carried
out with continuous cardiac monitoring. Although heart
rate was decreased by propranolol treatment in our data,
MAP remained stable and did not differ between groups.
This is in line with other similar studies in the rat CLP
model where significant reduction in heart rates by beta
blockade was not associated with hypotension or
decreased cardiac output [24,25]. It has been proposed
that beta-blockers improve survival in part by decreasing
heart rate and improving stroke volume, thereby safely
reducing cardiac work but this has yet to be confirmed in
a multicenter trial. A further limitation is that the first
dose of beta-blocker was given 30 minutes prior to the
onset of CLP. Thus, this very proximal pre-treatment dose
may not be a realistic replication of some forms of sepsis
in the clinical setting, when the time of onset of sepsis can
often not be predicted. A more ideal comparison of our
model would be in the major surgery, burn or trauma
patient where sepsis commonly occurs following the initial
insult and proximal pre-treatment (that is, pre-operatively)
or long term therapy (such as is commonly used in burn
injury) may allow for the beta-blocker to be present prior
to sepsis initiation. Further experiments examining post-
treatment with propranolol are warranted.
Sepsis is accompanied by metabolic changes resulting in
a catabolic state of increased energy expenditure, hypergly-
cemia and muscle loss, which can be modulated via beta-
receptors. This study demonstrated that in a rat model,
beta-blockade may improve the metabolic and physiologi-
cal alterations caused during sepsis by increasing the
ATP/ADP ratio in the lungs. Additionally, in this study
lung NAD+, a marker of enhanced mitochondrial oxida-
tive phosphorylation [16], was increased at 24 hours post-
CLP in the propranolol-treated rats. This energy from
glucose and fatty acid metabolism is transferred to NAD+
by reduction to NADH, as part of beta oxidation, glycoly-
sis and the citric acid cycle. The electrons carried by the
NADH that is produced in the cytoplasm are transferred
into the mitochondrion (to reduce mitochondrial NAD+)
by mitochondrial shuttles, such as the malate-aspartate
shuttle. The mitochondrial NADH is then oxidized in turn
to NAD+ by the electron transport chain, which pumps
protons across a membrane and generates ATP through
oxidative phosphorylation. As such, for sepsis, increased
NAD+ concentrations show the shift towards ATP
production and shift to oxidative phsopshorylation (as
confirmed by increased [ATP/ADP] ratios). It is unclear
why the differences in NAD+ are not evident at six hours
post-sepsis in the two groups, but become more
pronounced at 24 hours post-sepsis injury. Similarly, the
ATP/ADP ratio is siginificantly different at six hours, but
these differences are not observed at 24 hours. Additional
targeted metabolic research will be required to understand
further the role of propranolol on metabolic function in
the lung following sepsis. This may also include the need
for later timepoints following the septic insult to under-
stand the kinetics of these metabolic changes further.
Another marker that was altered in propranolol-treated
rat lungs was the PUFA/MUFA ratio. PUFA/MUFA ratio
is a surrogate marker of lipid peroxidation [16,26]. This
result indicates that propranolol administration is having
an anti(per)oxidant effect on the rats.
During sepsis, unregulated inflammatory cytokines,
including the inflammatory cytokine TNF-a, can result
in organ failure and severe pathologic inflammation [9].
This study demonstrated that non-selective beta-block-
ade decreased TNF-a levels both in plasma and in lung
tissue at 24 hours post-induction of sepsis. Studies exist
showing both an increase and a decrease in TNF-a
levels following propranolol treatment. Recent studies in
the CLP rat model and beta-1 blockade showed a
decrease in TNF-a levels measured in plasma and intra-
peritoneal fluid [24,27]. In other studies of experimental
sepsis, TNF-a was either unchanged [25] or increased
[28]. These discrepancies in TNF-a expression are most
likely due to the location and timing of cytokine mea-
surement or the type of beta-receptor blocked. Sepsis
has been described as displaying a variety of responses
within the body compartments [29] and different micro-
environments of the body are likely to see a relative
increase or decrease in inflammatory cytokines due to
sepsis [13]. Further, significant temporal changes in
cytokine expression were observed in a rat CLP model
of sepsis and timing of cytokine sampling must be con-
sidered [27]. Also, TNF-a expression may be different
with a non-specific beta-blocker as used in this study
when compared with studies utilizing beta-1 specific
Wilson et al. Critical Care 2013, 17:R195
http://ccforum.com/content/17/5/R195
Page 6 of 8
blockade. The mechanisms of beta-adrenergic immune
modulation are not well understood but are thought to
occur through regulation of NF-B expression [9,27].
Studies suggest that immune modulation can be either
pro-inflammatory or anti-inflammatory based on
whether beta2 or beta1 receptors are blocked, respec-
tively, [9] and the results of our study warrant future
studies of this complex immune modulation.
This study is the first to describe increased HO-1 levels in
the lungs of septic rats treated with a beta-blocker. Although
not all studies show a beneficial role for HO-1 overexpres-
sion [30,31], the vast majority of the literature demonstrates
that it confers profound protection in several models of lung
injury, as well as systemic inflammatory diseases, such as
sepsis [32]. HO-1 has been shown to have cytoprotective
effects through regulation of apoptosis as well as anti-
inflammatory effects, such as decreasing the levels of TNF-a
in serum [33]. The potential use of HO-1 clinically has been
suggested using gene delivery methods, but the ability to up-
regulate HO-1 expression using a beta-blocker would be a
promising alternative to difficult gene-therapy delivery
methods and warrants further investigation.
Conclusions
In conclusion, this study demonstrated a significant survi-
val advantage for septic rats given a non-specific beta-
blocker. This outcome benefit may be due, not only to
previously described effects on the myocardium and
muscle, but also benefits on lung metabolism, immune
regulation and enhanced pulmonary HSP expression.
Further studies are needed to determine the mechanisms,
dosages and timing of beta-blockade that may optimally
improve outcome in sepsis. This study suggests that
propranolol treatment could be beneficial to decrease
mortality from sepsis in humans.
Key messages
• Early treatment (30 minutes pre-injury and dosed
for the first 24 hours) with propranolol can improve
survival in rodents following polymicrobial sepsis.
• Propranolol administration during septic shock
reduced heart rate 20% to 30% without a significant
effect on blood pressure.
• Propranolol administration during septic shock can
reduce expression of TNF-a in lung and plasma.
• Propranolol administration during septic shock can
attenuate lung tissue metabolic dysfunction.
• Propranolol administration during septic shock can
induce protective HO-1 (HSP 32) expression.
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